Monique Nijhuis

List of Publications by Year
in descending order

33 papers	2,095 citations	516710 16 h-index	434195 31 g-index
34 all docs	34 docs citations	34 times ranked	3392 citing authors

#	Article	IF	Citations
1	In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center. Open Forum Infectious Diseases, 2022, 9, ofab553.	0.9	4
2	Human microglial models to study HIV infection and neuropathogenesis: a literature overview and comparative analyses. Journal of NeuroVirology, 2022, 28, 64-91.	2.1	15
3	Characterization of HIV-1 Infection in Microglia-Containing Human Cerebral Organoids. Viruses, 2022, 14, 829.	3.3	24
4	A publicâ€“private partnership model for COVID-19 diagnostics. Nature Biotechnology, 2021, 39, 1182-1184.	17.5	4
5	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Science Translational Medicine, 2020, 12, .	12.4	17
6	Evidence for HIV-1 cure after CCR5Î”32/Î”32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV,the, 2020, 7, e340-e347.	4.7	151
7	An inkjet-printed polysaccharide matrix for on-chip sample preparation in point-of-care cell counting chambers. RSC Advances, 2020, 10, 18062-18072.	3.6	3
8	Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Î”32 Homozygous Stem Cells. Clinical Infectious Diseases, 2019, 68, 684-687.	5.8	42
9	A trip down memory lane with Retrovirology. Retrovirology, 2019, 16, 22.	2.0	0
10	HIV-1 remission following CCR5Î”32/Î”32 haematopoietic stem-cell transplantation. Nature, 2019, 568, 244-248.	27.8	447
11	Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. Annals of Internal Medicine, 2018, 169, 674.	3.9	59
12	Development of sensitive dd<scp>PCR</scp> assays to reliably quantify the proviral <scp>DNA</scp> reservoir in all common circulating <scp>HIV</scp> subtypes and recombinant forms. Journal of the International AIDS Society, 2018, 21, e25185.	3.0	16
13	All-printed cell counting chambers with on-chip sample preparation for point-of-care CD4 counting. Biosensors and Bioelectronics, 2018, 117, 659-668.	10.1	13
14	Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance. Retrovirology, 2018, 15, 1.	2.0	23
15	Digital PCR as a tool to measure HIV persistence. Retrovirology, 2018, 15, 16.	2.0	66
16	A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Scientific Reports, 2017, 7, 41968.	3.3	110
17	High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients. Clinical Infectious Diseases, 2017, 64, 1092-1097.	5.8	11
18	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395

#	Article	IF	Citations
19	CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathogens, 2016, 12, e1005701.	4.7	221
20	Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. PLoS ONE, 2015, 10, e0132430.	2.5	26
21	Short Communication:In VitroAccumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine. AIDS Research and Human Retroviruses, 2015, 31, 851-858.	1.1	3
22	Robust regression methods for real-time polymerase chain reaction. Analytical Biochemistry, 2015, 480, 34-36.	2.4	7
23	Complex T-Cell Receptor Repertoire Dynamics Underlie the CD8+T-Cell Response to HIV-1. Journal of Virology, 2015, 89, 110-119.	3.4	23
24	Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 573-580.	3.0	7
25	Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses. Journal of the International AIDS Society, 2014, 17, 19755.	3.0	6
26	Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model. Retrovirology, 2014, 11, 113.	2.0	10
27	Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients. PLoS ONE, 2014, 9, e110749.	2.5	32
28	Graft Versus HIV-1 Reservoir Effect after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1234-1234.	1.4	0
29	Failure of Treatment with Firstâ€Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V. Journal of Infectious Diseases, 2009, 200, 698-709.	4.0	32
30	Novel mechanisms of HIV protease inhibitor resistance. Current Opinion in HIV and AIDS, 2008, 3, 627-632.	3.8	9
31	A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. PLoS Medicine, 2007, 4, e36.	8.4	146
32	HIV protease resistance and viral fitness. Current Opinion in HIV and AIDS, 2007, 2, 108-115.	3.8	13
33	Rapid and Sensitive Routine Detection of All Members of the Genus Enterovirus in Different Clinical Specimens by Real-Time PCR. Journal of Clinical Microbiology, 2002, 40, 3666-3670.	3.9	155